

# MarÃ-a del Valle Palomo Ruiz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3100837/publications.pdf>

Version: 2024-02-01

42  
papers

1,686  
citations

279798

23  
h-index

289244

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3156  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo. ACS Chemical Neuroscience, 2012, 3, 963-971.	3.5	139
2	Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice. Biological Psychiatry, 2014, 75, 198-206.	1.3	101
3	Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. Journal of Medicinal Chemistry, 2011, 54, 8461-8470.	6.4	91
4	Photoligation of an Amphiphilic Polymer with Mixed Coordination Provides Compact and Reactive Quantum Dots. Journal of the American Chemical Society, 2015, 137, 5438-5451.	13.7	91
5	Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry, 2011, 54, 4042-4056.	6.4	84
6	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2012, 55, 1645-1661.	6.4	76
7	Purple-, Blue-, and Green-Emitting Multishell Alloyed Quantum Dots: Synthesis, Characterization, and Application for Ratiometric Extracellular pH Sensing. Chemistry of Materials, 2017, 29, 7330-7344.	6.7	74
8	Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. Journal of Immunology, 2013, 190, 5000-5011.	0.8	71
9	Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease.. ACS Chemical Neuroscience, 2013, 4, 350-360.	3.5	69
10	Delivery and Tracking of Quantum Dot Peptide Bioconjugates in an Intact Developing Avian Brain. ACS Chemical Neuroscience, 2015, 6, 494-504.	3.5	67
11	T cells control the generation of nanomolar-affinity anti-glycan antibodies. Journal of Clinical Investigation, 2017, 127, 1491-1504.	8.2	63
12	PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE, 2011, 6, e15937.	2.5	59
13	Dual inhibitor of PDE7 and GSK-3 $\alpha$ VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology, 2013, 64, 205-214.	4.1	56
14	Subtly Modulating Glycogen Synthase Kinase 3 $\beta$ : Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry, 2017, 60, 4983-5001.	6.4	52
15	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences, 2013, 70, 3449-3462.	5.4	51
16	UV and Sunlight Driven Photoligation of Quantum Dots: Understanding the Photochemical Transformation of the Ligands. Journal of the American Chemical Society, 2015, 137, 2704-2714.	13.7	45
17	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Scientific Reports, 2017, 7, 43545.	3.3	40
18	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opinion on Therapeutic Patents, 2017, 27, 657-666.	5.0	40

#	ARTICLE	IF	CITATIONS
19	TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1183-1196.	3.5	37
20	5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3 $\beta$ (GSK-3 $\beta$ ) and phosphodiesterase 7 (PDE7) inhibitors: Determination of blood-brain barrier penetration and binding to human serum albumin. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 677-684.	4.0	30
21	The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy. <i>Current Medicinal Chemistry</i> , 2011, 18, 3028-3034.	2.4	28
22	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. <i>Molecular Neurodegeneration</i> , 2018, 13, 19.	10.8	28
23	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. <i>British Journal of Pharmacology</i> , 2021, 178, 1316-1335.	5.4	28
24	Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders. <i>ACS Chemical Neuroscience</i> , 2014, 5, 194-204.	3.5	25
25	Identification <i>in Silico</i> and Experimental Validation of Novel Phosphodiesterase 7 Inhibitors with Efficacy in Experimental Autoimmune Encephalomyelitis Mice. <i>ACS Chemical Neuroscience</i> , 2012, 3, 793-803.	3.5	24
26	3,4-Dihydroxyphenylalanine Peptides as Nonperturbative Quantum Dot Sensors of Aminopeptidase. <i>ACS Nano</i> , 2016, 10, 6090-6099.	14.6	23
27	A preliminary investigation of phosphodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. <i>Journal of Chemical Neuroanatomy</i> , 2017, 80, 27-36.	2.1	23
28	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. <i>Neuropharmacology</i> , 2017, 116, 174-187.	4.1	23
29	Controlling the Architecture, Coordination, and Reactivity of Nanoparticle Coating Utilizing an Amino Acid Central Scaffold. <i>Journal of the American Chemical Society</i> , 2015, 137, 16084-16097.	13.7	22
30	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 403-414.	4.1	22
31	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1585-1607.	6.4	20
32	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 522-526.	5.2	19
33	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. <i>Journal of Neurochemistry</i> , 2012, 122, 1193-1202.	3.9	15
34	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. <i>PLoS ONE</i> , 2016, 11, e0162723.	2.5	10
35	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-templated Synthesis. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 19344-19354.	13.8	9
36	Efficient Assembly of Quantum Dots with Homogenous Glycans Derived from Natural N-Linked Glycoproteins. <i>Bioconjugate Chemistry</i> , 2018, 29, 3144-3153.	3.6	7

#	ARTICLE	IF	CITATIONS
37	CdSe quantum dots evaluation in primary cellular models or tissues derived from patients. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 30, 102299.	3.3	7
38	Allosteric Modulation of GSK-3 $\beta$ as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7367.	4.1	5
39	Effect of Clinically Used Microtubule Targeting Drugs on Viral Infection and Transport Function. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3448.	4.1	5
40	TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimer's Disease Patients. <i>Biomedicines</i> , 2022, 10, 385.	3.2	3
41	CdSe Quantum Dots in Human Models Derived from ALS Patients: Characterization, Nuclear Penetration Studies and Multiplexing. <i>Nanomaterials</i> , 2021, 11, 671.	4.1	2
42	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis. <i>Angewandte Chemie</i> , 2021, 133, 19493-19503.	2.0	2